NCT01135511

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

A Phase II, Prospective, Randomized, Double Masked/Investigator Masked, Vehicle And Comparator (Sodium Hyaluronate Eye Drops) Controlled, Dose Ranging Study Of CP-690,550 Eye Drops In Subjects With Dry Eye Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 285 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.

Conditions

• Dry Eye Syndromes

Interventions

Type	Name	Description
DRUG	CP-690,550 Eye drops	Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
DRUG	CP-690,550 Eye drops	Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
DRUG	CP-690,550 Eye drops	Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
DRUG	CP-690,550 Eye drops-vehicle	Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
DRUG	Sodium Hyaluronate	Ophthalmic topical solution, dosed 6 times/day, 8 weeks

Timeline

• Start date: 2010-07-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2010-06-02
• Last updated: 2013-05-07
• Results posted: 2013-05-07

Locations

28 sites across 2 countries: Japan, South Korea